Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma [0.03%]
Burkitt淋巴瘤TP53突变状态的肿瘤内异质性对治疗的影响
Enrico Derenzini,Ilaria Iacobucci,Claudio Agostinelli et al.
Enrico Derenzini et al.
Therapeutic implications of intra-tumor heterogeneity are still undefined. In this study we report a genetic and functional analysis aimed at defining the mechanisms of chemoresistance in a 43-year old woman affected by stage IVB Burkitt ly...
Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) [0.03%]
IKZF1缺失对费城染色体阴性儿童B细胞前体急性淋巴细胞白血病信号转导通路的影响
Naomi E van der Sligte,Frank J G Scherpen,Arja Ter Elst et al.
Naomi E van der Sligte et al.
Background: IKZF1 deletions are an unfavorable prognostic factor in children with Philadelphia chromosome positive (Ph(+)) as well as negative (Ph(-)) acute lymphoblastic leukemia (ALL). Although IKZF1 deletions occur in ...
Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study [0.03%]
急性髓系白血病组织因子依赖性和非依赖性凝血激活路径：单中心队列研究
Christina Dicke,Ali Amirkhosravi,Brigitte Spath et al.
Christina Dicke et al.
Background: In acute myeloid leukemia (AML), disseminated intravascular coagulation (DIC) contributes to morbidity and mortality, but the underlying pathomechanisms remain incompletely understood. ...
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma [0.03%]
Syk抑制剂的抗增殖和促凋亡效应及其在多发性骨髓瘤中的作用分析研究
Ruth-Miriam Koerber,Stefanie Andrea Erika Held,Annkristin Heine et al.
Ruth-Miriam Koerber et al.
Background: Multiple myeloma (MM) is a clonal B cell malignancy characterized by proliferation of malignant plasma cells in the bone marrow. Despite high-dose melphalan therapy with autologous stem cell transplantation (A...
Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma [0.03%]
Z-BeEAM（伊布替莫单抗，苯达莫司汀，依托泊苷，阿糖胞苷，美法仑）在自体干细胞移植前用于治疗难治性大B细胞淋巴瘤是安全且有效的
Magalie P Tardy,Lauris Gastaud,Mario Ojeda-Uribe et al.
Magalie P Tardy et al.
Background: Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan...
Melanoma tumor growth is accelerated in a mouse model of sickle cell disease [0.03%]
一个镰状细胞病小鼠模型中的黑色素瘤肿瘤生长加速
Jintao Wang,Jennifer Tran,Hui Wang et al.
Jintao Wang et al.
Background: The effect of sickle cell disease (SCD) on tumor growth is unknown. Sickled red blood cells may form aggregates within the microvasculature of hypoxic tumors and reduce blood flow leading to impairment of tumo...
Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response [0.03%]
蛋白质组分析表明表达非小细胞肺癌相关表皮生长因子受体变异体的HEK293细胞会诱导热休克反应
Arpana Kamath,Ann M Joseph,Kumud Gupta et al.
Arpana Kamath et al.
In view of the fact that certain non small cell lung carcinoma associated epidermal growth factor receptor mutations keep the receptor constitutively active, the downstream effectors of altered activity of mutant receptors are largely unkno...
Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma [0.03%]
氟达拉滨、环磷酰胺和利妥昔单抗方案治疗复发的I至II级滤泡性淋巴瘤的长期有效性和安全性以及随后使用伊布替莫单抗 tiuxetan巩固疗法
Francesco Pisani,Rosa Sciuto,Maria Laura Dessanti et al.
Francesco Pisani et al.
Background: In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with (90)Yttrium- ibritumomab tiuxetan ((90)Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were trea...
Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies [0.03%]
澳大利亚血液系统癌症幸存者的临床医生在监测药物顺应性吗？两项横断面研究
Marita C Lynagh,Tara Clinton-McHarg,Alix Hall et al.
Marita C Lynagh et al.
Background: Hematological cancer survivors are growing in number and increasingly rely on oral therapy. Given known poor outcomes associated with non-adherence and previous evidence that many patients do not fully adhere ...
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia [0.03%]
TET2、SRSF2、ASXL1和SETBP1突变对慢性嗜单核细胞白血病患者生存期的影响
Yajuan Cui,Hongyan Tong,Xin Du et al.
Yajuan Cui et al.
Background: Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm classified in the myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category. Molecular abnormalities are reported in about 90 % of pat...